Drive Wealth Administration LLC raised its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 10.4% within the second quarter, in keeping with the corporate in its most up-to-date disclosure with the SEC. The agency owned 4,232 shares of the corporate’s inventory after buying an extra 400 shares in the course of the quarter. Drive Wealth Administration LLC’s holdings in AstraZeneca have been price $330,000 as of its most up-to-date submitting with the SEC.
A number of different institutional buyers additionally not too long ago made modifications to their positions in AZN. Massachusetts Wealth Administration bought a brand new stake in shares of AstraZeneca in the course of the 2nd quarter price roughly $226,000. Retireful LLC acquired a brand new place in AstraZeneca in the course of the second quarter price $2,019,000. Ritholtz Wealth Administration boosted its place in AstraZeneca by 12.7% in the course of the second quarter. Ritholtz Wealth Administration now owns 66,235 shares of the corporate’s inventory price $5,166,000 after buying an extra 7,478 shares within the final quarter. Waldron Personal Wealth LLC acquired a brand new stake in AstraZeneca within the second quarter valued at $275,000. Lastly, Summit Monetary LLC bought a brand new place in shares of AstraZeneca within the second quarter valued at $438,000. 20.35% of the inventory is at the moment owned by hedge funds and different institutional buyers.
AstraZeneca Buying and selling Up 0.4 %
Shares of AstraZeneca inventory opened at $87.62 on Monday. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week excessive of $87.68. The enterprise’s fifty day shifting common is $80.81 and its two-hundred day shifting common is $75.00. The corporate has a fast ratio of 0.69, a present ratio of 0.89 and a debt-to-equity ratio of 0.69. The agency has a market cap of $271.67 billion, a PE ratio of 42.95, a P/E/G ratio of 1.65 and a beta of 0.47.
AstraZeneca (NASDAQ:AZN – Get Free Report) final launched its earnings outcomes on Thursday, July twenty fifth. The corporate reported $0.99 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.01. AstraZeneca had a return on fairness of 29.34% and a web margin of 13.11%. The agency had income of $12.45 billion for the quarter, in comparison with the consensus estimate of $12.62 billion. Throughout the identical interval within the prior 12 months, the enterprise posted $1.08 earnings per share. The agency’s income for the quarter was up 9.1% in comparison with the identical quarter final 12 months. Analysts anticipate that AstraZeneca PLC will put up 4.06 earnings per share for the present 12 months.
AstraZeneca Cuts Dividend
The enterprise additionally not too long ago declared a Semi-Annual dividend, which can be paid on Monday, September ninth. Shareholders of document on Friday, August ninth can be issued a $0.49 dividend. The ex-dividend date of this dividend is Friday, August ninth. This represents a dividend yield of 1.8%. AstraZeneca’s dividend payout ratio (DPR) is presently 48.04%.
Wall Avenue Analysts Forecast Progress
AZN has been the subject of a number of current analysis reviews. TD Cowen boosted their worth goal on shares of AstraZeneca from $90.00 to $95.00 and gave the inventory a “purchase” ranking in a analysis report on Monday, August twelfth. Citigroup upgraded shares of AstraZeneca to a “strong-buy” ranking in a analysis report on Monday, June twenty fourth. The Goldman Sachs Group started protection on AstraZeneca in a analysis report on Thursday, Could thirtieth. They set a “purchase” ranking and a $97.00 worth goal for the corporate. Barclays raised AstraZeneca to a “strong-buy” ranking in a analysis notice on Monday, June twenty fourth. Lastly, Argus boosted their worth goal on AstraZeneca from $80.00 to $85.00 and gave the inventory a “purchase” ranking in a report on Thursday, Could thirtieth. Three analysis analysts have rated the inventory with a maintain ranking, six have given a purchase ranking and three have given a robust purchase ranking to the corporate’s inventory. Primarily based on information from MarketBeat.com, AstraZeneca presently has a mean ranking of “Purchase” and a consensus goal worth of $89.75.
Get Our Newest Evaluation on AZN
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical firm, focuses on the invention, improvement, manufacture, and commercialization of prescription medicines. The corporate’s marketed merchandise embody Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Tales
Obtain Information & Rankings for AstraZeneca Every day – Enter your electronic mail deal with beneath to obtain a concise each day abstract of the most recent information and analysts’ rankings for AstraZeneca and associated firms with MarketBeat.com’s FREE each day electronic mail e-newsletter.
